Retrieved on:
Tuesday, January 30, 2024
LONDON, 19 January 2024: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, announces the unaudited estimated Net Asset Value (“NAV”) of the Company for the date ended 31 December 2023 as follows:
Key Points:
- LONDON, 19 January 2024: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, announces the unaudited estimated Net Asset Value (“NAV”) of the Company for the date ended 31 December 2023 as follows:
Retrieved on:
Tuesday, January 30, 2024
LONDON, 19 January 2024: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a global venture capital company focused on investing in breakthrough biotechnology companies, provides a financial update on its expected returns from the Harpoon Therapeutics (NASDAQ: HARP) ("Harpoon") acquisition by Merck (NYSE: MRK) following the announcement that Merck (known as MSD outside the United States and Canada), through a subsidiary, agreed to acquire Harpoon for $23.00 per share in cash for an approximate total equity value of $680 million.
Key Points:
- LONDON, 19 January 2024: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a global venture capital company focused on investing in breakthrough biotechnology companies, provides a financial update on its expected returns from the Harpoon Therapeutics (NASDAQ: HARP) ("Harpoon") acquisition by Merck (NYSE: MRK) following the announcement that Merck (known as MSD outside the United States and Canada), through a subsidiary, agreed to acquire Harpoon for $23.00 per share in cash for an approximate total equity value of $680 million.
- The sale of Harpoon is expected to deliver net proceeds to Arix of approximately $18.9 million (£14.9 million [1]).
- This acquisition by Merck provides significant potential for bringing life-saving treatment to cancer patients as they enhance their oncology pipeline.
- [1] At prevailing GBP/USD FX rate on 18 January 2024.
LONDON, 8 January 2024: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a global venture capital company focused on investing in breakthrough biotechnology companies, is pleased to note that its portfolio company, Harpoon Therapeutics (NASDAQ: HARP), is to be acquired by Merck (NYSE: MRK).
Key Points:
- LONDON, 8 January 2024: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a global venture capital company focused on investing in breakthrough biotechnology companies, is pleased to note that its portfolio company, Harpoon Therapeutics (NASDAQ: HARP), is to be acquired by Merck (NYSE: MRK).
- The two companies have entered into a definitive agreement under which Merck (known as MSD outside the United States and Canada), through a subsidiary, will acquire Harpoon for $23.00 per share in cash for an approximate total equity value of $680 million.
- Arix will provide a full financial update for its shareholders in due course.
- The announcement can be accessed on Harpoon Therapeutics’ website at: www.harpoontx.com and the full text of the announcement from the company is contained below.
Retrieved on:
Saturday, December 30, 2023
LONDON, 10 November 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, notes that its Core Portfolio company, Aura Biosciences (NASDAQ: AURA) (“Aura”), has announced the closing of its underwritten public offering of 11,000,000 shares of its common stock at a price to the public of $9.00 per share.
Key Points:
- LONDON, 10 November 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, notes that its Core Portfolio company, Aura Biosciences (NASDAQ: AURA) (“Aura”), has announced the closing of its underwritten public offering of 11,000,000 shares of its common stock at a price to the public of $9.00 per share.
- The Company received net proceeds from the Offering, after deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company, of approximately $92.6 million.
- The holding value of these shares will continue to be determined by the market price of Aura’s shares.
- The full text from Aura’s announcement can be accessed on the Aura Biosciences website here: https://ir.aurabiosciences.com/press-releases
For more information on Arix, please contact:
Retrieved on:
Thursday, December 14, 2023
LONDON, 13 December 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, announces the unaudited estimated Net Asset Value (“NAV”) of the Company for the date ended 30 November 2023 as follows:
Key Points:
- LONDON, 13 December 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, announces the unaudited estimated Net Asset Value (“NAV”) of the Company for the date ended 30 November 2023 as follows:
Retrieved on:
Tuesday, November 7, 2023
United Kingdom,
Biotechnology,
Sorriso,
Ulcerative colitis,
Pharmacokinetics,
PK,
IBD,
LSE,
Safety,
Patient,
Pharmaceutical industry LONDON, 1 November 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, notes that its Core Portfolio company, Sorriso Pharmaceuticals (“Sorriso”), has announced that the first subject has been dosed in the Company’s Phase 1/1b clinical program of SOR102.
Key Points:
- LONDON, 1 November 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, notes that its Core Portfolio company, Sorriso Pharmaceuticals (“Sorriso”), has announced that the first subject has been dosed in the Company’s Phase 1/1b clinical program of SOR102.
- This Phase 1 trial is a randomized, double-blind study consisting of three parts.
- Part 3 will evaluate safety, tolerability, PK, and clinical and biological activity of multiple oral doses of SOR102 in patients with mild to severe ulcerative colitis.
- The trial is expected to enrol up to 60 adult participants at sites in the United Kingdom and Europe.
Retrieved on:
Thursday, October 26, 2023
Arix’s holding value will continue to be determined by the market price of Harpoon’s shares.
Key Points:
- Arix’s holding value will continue to be determined by the market price of Harpoon’s shares.
- Harpoon intends to use the net proceeds to fund its clinical development programs from its platforms, including ongoing as well as future late-stage clinical studies of HPN328.
- Robert Lyne, CEO of Arix, stated: “Following the announcement of strong data sets across Harpoon’s best-in-class immunotherapy pipeline, we welcome this private placement alongside the addition of quality new investors on the register.
- This placement represents an additional vote of confidence by these new and existing investors, further underpinning Harpoon with a strong cash runway going into 2026.”
The full text from Harpoon’s announcement is reproduced below, and can be accessed on Harpoon Therapeutics’ website at: www.harpoontx.com .
Retrieved on:
Tuesday, October 17, 2023
LONDON, 6 October 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, announces the unaudited estimated Net Asset Value (“NAV”) of the Company for the date ended 30 September 2023 as follows:
Key Points:
- LONDON, 6 October 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, announces the unaudited estimated Net Asset Value (“NAV”) of the Company for the date ended 30 September 2023 as follows:
Retrieved on:
Wednesday, September 27, 2023
LONDON, 27 September 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, announces its interim results for the six months ended 30 June 2023.
Key Points:
- LONDON, 27 September 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, announces its interim results for the six months ended 30 June 2023.
- “Following the announcement of the strategic review in July 2023, the Board has been exploring a range of strategic options for the Company.
- Currently, a number of options remain under active consideration and the Board is focused on evaluating these in conjunction with its advisers.
- Analysts wishing to join should register their interest by contacting Powerscourt on [email protected] or on +44 (0) 20 7290 1050.
Retrieved on:
Wednesday, September 27, 2023
We thank Robert for his significant contributions to Arix over the years and wish him well in the future.
Key Points:
- We thank Robert for his significant contributions to Arix over the years and wish him well in the future.
- “Going forward, the Board’s primary focus will be to maximise shareholder returns and unlock the value in the Arix portfolio.
- Consequently, the Board will determine appropriate Board and management arrangements following the outcome of the strategic review and update shareholders accordingly.
- The Board will maintain its decision-making responsibilities on all investment decisions.”
For more information on Arix, please contact:
